Insider Transactions in Q2 2021 at Cvs Health Corp (CVS)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
2,781
-4.36%
|
$230,823
$83.67 P/Share
|
|
Jun 15
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
67,552
-32.11%
|
$5,809,472
$86.0 P/Share
|
|
Jun 15
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,681
+23.79%
|
$4,072,222
$62.21 P/Share
|
|
Jun 07
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
37,594
-61.73%
|
$3,233,084
$86.6 P/Share
|
|
Jun 07
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Exercise of conversion of derivative security
|
Direct |
32,320
+34.67%
|
$1,745,280
$54.19 P/Share
|
|
May 31
2021
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-0.1%
|
$54,524
$86.44 P/Share
|
|
May 28
2021
|
Shawn M Guertin EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,706
+50.0%
|
$2,984,716
$86.44 P/Share
|
|
May 13
2021
|
Mary L Schapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
459
+6.02%
|
$38,556
$84.27 P/Share
|
|
May 13
2021
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+5.23%
|
$115,836
$84.27 P/Share
|
|
May 13
2021
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,468
+6.24%
|
$123,312
$84.27 P/Share
|
|
May 13
2021
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,470
+3.15%
|
$291,480
$84.27 P/Share
|
|
May 13
2021
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,446
+50.0%
|
$121,464
$84.27 P/Share
|
|
May 13
2021
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+50.0%
|
$115,836
$84.27 P/Share
|
|
May 13
2021
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,446
+3.81%
|
$121,464
$84.27 P/Share
|
|
May 10
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
109,469
-100.0%
|
$9,414,334
$86.0 P/Share
|
|
May 10
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
109,469
+50.0%
|
$6,787,078
$62.21 P/Share
|
|
May 07
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,477
-6.15%
|
$796,068
$84.0 P/Share
|
|
May 04
2021
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
4,905
-4.08%
|
$392,400
$80.0 P/Share
|
|
May 04
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
49,279
+50.0%
|
$2,858,182
$58.34 P/Share
|
|
Apr 21
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
103,423
-98.83%
|
$7,963,571
$77.0 P/Share
|
|
Apr 21
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
101,003
+49.41%
|
$5,454,162
$54.19 P/Share
|
|
Apr 03
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,705
-2.6%
|
$126,170
$74.3 P/Share
|
|
Apr 03
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-2.67%
|
$35,520
$74.3 P/Share
|
|
Apr 01
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36,310
-18.42%
|
$2,686,940
$74.3 P/Share
|
|
Apr 01
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
44,478
-11.51%
|
$3,291,372
$74.3 P/Share
|
|
Apr 01
2021
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
40,777
-12.84%
|
$3,017,498
$74.3 P/Share
|
|
Apr 01
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,710
+20.7%
|
$348,540
$74.3 P/Share
|
|
Apr 01
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,749
-16.96%
|
$499,426
$74.3 P/Share
|
|
Apr 01
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Payment of exercise price or tax liability
|
Direct |
10,584
-17.15%
|
$783,216
$74.3 P/Share
|
|
Apr 01
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
42,431
-40.75%
|
-
|
|
Apr 01
2021
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,211
-45.34%
|
$3,197,614
$74.3 P/Share
|
|
Apr 01
2021
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
90,351
-6.47%
|
$3,342,987
$37.15 P/Share
|
|
Apr 01
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
63,445
-26.36%
|
$4,694,930
$74.3 P/Share
|
|
Apr 01
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
79,714
-45.17%
|
$5,898,836
$74.3 P/Share
|